DDInter1635 DDInter1658
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine. Salmeterol was granted FDA approval on 4 February 1994.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Salmeterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Salmeterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salmeterol {u} (Compound) resembles {v} (Compound) Hexoprenaline
Salmeterol {u} (Compound) treats {v} (Disease) asthma
Salmeterol {u} (Compound) binds {v} (Gene) ADRB2
Salmeterol {u} (Compound) upregulates {v} (Gene) EDEM1
Salmeterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Salmeterol {u} (Compound) downregulates {v} (Gene) CDC20
Salmeterol {u} (Compound) causes {v} (Side Effect) Chronic obstructive pulmonary disease
Salmeterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrocortisone
Salmeterol may lead to a major life threatening interaction when taken with Labetalol
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Salmeterol (Compound) resembles Hexoprenaline (Compound)
Salmeterol (Compound) treats asthma (Disease)
Salmeterol (Compound) binds ADRB2 (Gene)
Salmeterol (Compound) upregulates EDEM1 (Gene)
Salmeterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Salmeterol (Compound) downregulates CDC20 (Gene)
Salmeterol (Compound) causes Chronic obstructive pulmonary disease (Side Effect)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone